KRRO at a glance
Korro Bio, Inc. (KRRO, SEC CIK 1703647) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 5, 2026 and Form 4 insider filings as recently as September 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Korro Bio, Inc. (KRRO) reported revenue of $6.4 million (up 181.5% from FY2024) and a net loss of $117.3 million. Diluted EPS was -$12.48.
- As of June 30, 2026, 23 institutional investment managers tracked by SignalX reported holding Korro Bio, Inc. (KRRO) shares worth $40.6 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by FORMELA JEAN FRANCOIS on September 14, 2026 of 31,888 shares at $14.12 per share.
- In the last 90 days, KRRO insiders reported 2 open-market purchases ($79K) and 16 open-market sales ($1.3M) on Form 4, a net sale of $1.2M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $6.4M
- +181.5% vs prior year
- Insiders · 90 days
- 2 buys · 16 sells
- Net −$1.2M
- 13F holders
- 23 funds
- $40.6M · +3 vs prior quarter
- Latest 8-K
- Aug 19, 2026
- Item 8.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- KRRO-110 REWRITE trial failure triggered AATD program transition from LNP delivery to KRRO-111’s GalNAc-conjugated delivery
- KRRO-121 remains preclinical, with first-in-human regulatory filing anticipated in the second half of 2026
- GalNAc-conjugated REO delivery lacks FDA-approved precedent, creating efficacy risk across KRRO-121 and KRRO-111
- Evolving tariffs since April 2025 may increase supply-chain costs and disrupt clinical-site operations
- Cash, cash equivalents and marketable securities totaled $137.9 million, projected to fund operations into the second half of 2028
AI summary of the KRRO 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 8.01: Other Events
- KRRO-121 Phase 1/2 trial submission to Australian Alfred Health Human Ethics Committee
- GalNAc-conjugated RNA editing oligonucleotide targeting hyperammonemia in Urea Cycle Disorders
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results for quarter ended June 30, 2026
- Press release furnished as Exhibit 99.1 contains financial results and management commentary
Item 1.01: Entry into a Material Definitive Agreement
- VenRock surrendered 1,000,000 common shares for no consideration, reducing immediately outstanding shares
- Korro issued immediately exercisable pre-funded warrants for 1,000,000 shares at a $0.001 exercise price with no expiration
Item EX-99.1: Item EX-99.1
- Q2 2026 net loss $18.9M, improving from $25.8M; six-month loss $38.5M versus $49.2M
- Cash, equivalents and marketable securities $137.9M, funding operations into the second half of 2028
AI summaries of KRRO 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for KRRO
Don't miss the next KRRO filing
- Alerts as it files. A push when KRRO files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut KRRO, by share count.
- Ask anything. An AI agent that reads every KRRO filing and answers with sources.
KRRO alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| FORMELA JEAN FRANCOIS | Sell | Sep 14, 2026 | 31,888 | $14.12 |
| FORMELA JEAN FRANCOIS | Sell | Sep 14, 2026 | 6,602 | $14.12 |
| Dolan Oliver | Sell | Sep 11, 2026 | 5 | $13.72 |
| FORMELA JEAN FRANCOIS | Sell | Sep 11, 2026 | 1,750 | $13.99 |
| FORMELA JEAN FRANCOIS | Sell | Sep 11, 2026 | 8,450 | $13.99 |
| Dolan Oliver | Sell | Sep 9, 2026 | 6 | $13.60 |
| Dolan Oliver | Sell | Sep 8, 2026 | 7,347 | $13.51 |
| FORMELA JEAN FRANCOIS | Sell | Aug 26, 2026 | 51 | $13.96 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.3M | $6.4M |
| Operating Income | - | -$91.9M | -$121.9M |
| Net Income | -$81.2M | -$83.6M | -$117.3M |
| Op. Margin | - | -4047.1% | -1906.4% |
| Net Margin | - | -3680.4% | -1834.5% |
| Balance Sheet | |||
| Total Assets | - | $226.2M | $113.5M |
| Equity | $169.9M | $160.4M | $51.4M |
| ROE | -47.8% | -52.1% | -228.0% |
| Per Share | |||
| EPS | - | $-9.37 | $-12.48 |
| Cash Flow | |||
| Operating CF | -$67.3M | -$60.1M | -$78.6M |
| CapEx | $7.8M | $17.9M | $518K |
Source: XBRL data in Korro Bio, Inc. (KRRO)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate KRRO share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 23 | $40.6M |
| Q1 2026 | 20 | $23.1M |
| Q4 2025 | 19 | $16.6M |
| Q3 2025 | 19 | $139.8M |
| Q2 2025 | 17 | $32.5M |
| Q1 2025 | 14 | $30.8M |
| Q4 2024 | 11 | $68.6M |
| Q3 2024 | 7 | $26.6M |
- BlackRock+357.6K (+78%)
- Vanguard Capital Management LLC+143.9K (+46%)
- State Street Corp+92.2K (+66%)
- Vanguard Portfolio Management LLC+75.0K (+50%)
- Goldman Sachs Group+66.4K (+131%)
- Renaissance Technologies LLC−25.7K (-19%)
- Morgan Stanley−18.6K (-45%)
- PNC Financial Services−637 (-77%)
- Bank of America Corp+51.7K
- D.E. Shaw & Co+34.2K
- T. Rowe Price Group+17.6K
- Dimensional Fund Advisors+11.4K
Source: 13F-HR filings on SEC EDGAR (aggregated from 130 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
KRRO filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 5, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Sep 14, 2026 | - | - | - |
| 4 | Sep 10, 2026 | - | - | - |
| 4 | Aug 28, 2026 | - | - | - |
| 4 | Aug 21, 2026 | - | - | - |
| 8-K | Aug 19, 2026 | - | Analysis | - |
| 4 | Aug 13, 2026 | - | - | - |
| 4 | Aug 13, 2026 | - | - | - |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 5, 2026 | - | - | - |
| SC 13G | Jul 29, 2026 | - | - | |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 17, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jun 24, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
KRRO SEC filings: frequently asked questions
Are KRRO insiders buying or selling?
In the last 90 days, Korro Bio, Inc. (KRRO) officers, directors and 10% owners reported 2 open-market purchases worth $78,809 by 1 insider and 16 open-market sales worth $1.3 million by 3 insiders on Form 4, a net sale of $1.2 million. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold KRRO stock?
As of June 30, 2026, the largest Korro Bio, Inc. (KRRO) holders among the 13F filers tracked by SignalX were BlackRock ($10.8 million), Vanguard Capital Management LLC ($6.0 million), AQR Capital Management ($3.9 million), State Street Corp ($3.1 million), Vanguard Portfolio Management LLC ($2.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was KRRO's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Korro Bio, Inc. (KRRO) reported revenue of $6.4 million (up 181.5% from FY2024) and a net loss of $117.3 million. Diluted EPS was -$12.48. The figures come from the XBRL data in the 10-K.
What did KRRO report in its latest 8-K?
Korro Bio, Inc. (KRRO) filed an 8-K on August 19, 2026 reporting Item 8.01 (Other Events). KRRO-121 Phase 1/2 trial submission to Australian Alfred Health Human Ethics Committee.
What are the latest KRRO SEC filings?
Korro Bio, Inc. (KRRO) filed its latest 10-K annual report on March 12, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on October 5, 2026 and a Form 4 insider filing on September 15, 2026.
What is KRRO's SEC CIK number?
Korro Bio, Inc. (KRRO)'s SEC Central Index Key (CIK) is 1703647. EDGAR lists every KRRO filing under that number.
Ask anything about KRRO
The research agent reads KRRO's filings, financials, insider trades and 13F holders, then answers with sources.